Takeda Pharmaceutical Co. (NYSE:TAK) Sees Large Increase in Short Interest

Key Points

• Short interest in Takeda Pharmaceutical Co. has surged by **81.5%**, reaching a total of **8,220,000 shares** as of July 31st, indicating increased investor bearishness.
• Institutional investors now own **9.17%** of Takeda Pharmaceutical's stock, with several firms significantly increasing their positions during the 2nd quarter of the year.
• Despite reporting earnings of **$0.52 per share**, which surpassed estimates, Takeda's revenue of **$7.45 billion** fell short of analyst predictions of **$7.96 billion**.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 8,220,000 shares, agrowthof81.5% from the July 15th total of 4,530,000 shares. Based on an average trading volume of 3,280,000 shares, the days-to-cover ratio is presently 2.5 days. Approximately0.3% of the shares of the company are short sold. Approximately0.3% of the shares of the company are short sold. Based on an average trading volume of 3,280,000 shares, the days-to-cover ratio is presently 2.5 days.

Takeda Pharmaceutical Stock Performance

TAK stock traded down $0.1850 on Thursday, reaching $15.2950. 3,385,547 shares of the company were exchanged, compared to its average volume of 2,556,395. Takeda Pharmaceutical has a 12 month low of $12.80 and a 12 month high of $15.56. The stock's fifty day moving average price is $14.80 and its 200 day moving average price is $14.65. The firm has a market capitalization of $48.67 billion, a PE ratio of 50.98 and a beta of 0.22. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, research analysts anticipate that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of TAK. GAMMA Investing LLC increased its holdings in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after buying an additional 1,296 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Takeda Pharmaceutical by 5.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock valued at $319,000 after buying an additional 1,098 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Takeda Pharmaceutical by 48.6% in the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after purchasing an additional 14,831 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at $262,000. Institutional investors own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.